glucagon has been researched along with 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide) | Trials (3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide) | Recent Studies (post-2010) (3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 10 | 0 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giacca, A; Kawamori, R; Kim, T; Klement, P; Lam, TK; Uchino, H; Williams, W; Yoshii, H | 1 |
1 other study(ies) available for glucagon and 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide
| Article | Year |
|---|---|
FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
Topics: Animals; Benzimidazoles; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Dogs; Fatty Acids, Nonesterified; Glucagon; Glucose; Glucose Clamp Technique; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin, Isophane; Liver; Male; PPAR gamma; Tritium | 2005 |